Neurogene Inc (NGNE)
40.67
+4.25
(+11.67%)
USD |
NASDAQ |
Jul 01, 16:00
40.59
-0.08
(-0.20%)
After-Hours: 20:00
Neurogene Shareholders Equity (Quarterly): 170.78M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 170.78M |
| September 30, 2023 | -183.21M |
| Date | Value |
|---|---|
| June 30, 2023 | -169.05M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-183.21M
Minimum
Sep 2023
170.78M
Maximum
Mar 2024
-60.50M
Average
-169.05M
Median
Jun 2023
Shareholders Equity (Quarterly) Benchmarks
| Taysha Gene Therapies Inc | 53.85M |
| CEL-SCI Corp | 14.30M |
| AIM ImmunoTech Inc | 4.826M |
| IGC Pharma Inc | 7.321M |
| NovaBay Pharmaceuticals Inc | 0.16M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 195.35M |
| Total Liabilities (Quarterly) | 24.57M |